Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS747158 · 4 trials · 4 indications
The rest flurpiridaz dose to be used for subsequent efficacy studies was determined by a modeling method that simulated a range of injected doses using a single fixed injected dose at rest in each subject and a range of acquisition durations. From this, a dose acquisition time product (DATP was determined for each subject that specified the minimal dose for a given acquisition duration that yielded an image in that subject that was negligibly affected by photon counting statistics. Descriptive statistics were used to identify an appropriate rest dose for the population. No other statistical tests were performed
Diagnostic efficacy of one-day rest/stress BMS747158 PET MPI is measured by sensitivity as compared to single photon emission computed tomography (SPECT)MPI in the detection of coronary artery disease (CAD)using angiography or three-month cardiac events as the truth standard.
The stress flurpiridaz dose for subsequent same-day rest-stress efficacy studies was determined as a multiple of the rest dose by computer modeling. Images derived only from rest flurpiridaz administration were blended using image analysis with images derived only from administration of flurpiridaz following exercise or adenosine stress. The blending fraction that resulted in negligible change in reader interpretation of defect severity was determined for each subject. The minimum value that met this criterion for all subjects was used to calculate the ratio of the stress dose to the rest dose as a function of the delay between administration of the two doses for both adenosine stress and exercise stress separately. No statistical analysis was performed.
Diagnostic efficacy of one-day rest/stress BMS747158 PET MPI is measured by specificity as compared to single photon emission computed tomography (SPECT)MPI in the detection of coronary artery disease (CAD)using angiography or three-month cardiac events as the truth standard.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: dose range and dose interval | EXPERIMENTAL | Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period. |
| Cohort 2: Pharm&exercise stress Efficacy | EXPERIMENTAL | Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress For the Pharmacologic (Adenosine) Stress: * Doses at rest to range between 2.9 and 3.4 mCi. * Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi. For the Exercise Stress: * Doses at rest were to range between 1.7 and 2.0 mCi. * Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi. |
| Single Arm | OTHER | Single arm PK study |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS747158 | DRUG | dosages at rest and at stress were not to exceed a total of 14 mCi. Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period. Cohort 2: Patients to recieve IV bolus injections of BMS747158: For the Pharmacologic (Adenosine) Stress: * Doses at rest were to range between 2.9 and 3.4 mCi. * Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi. For the Exercise Stress: * Doses at rest were to range between 1.7 and 2.0 mCi. * Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi. |
| [3H] BMS747158 | DRUG | Single bolus intravenous injection of \[3H\] BMS747158 |
Inclusion Criteria: * Provide signed IC prior to undergoing any study procedures * Be male or nonpregnant female, between the ages of 18 to 75 years, inclusive * Have:A rest/stress SPECT imaging study (either exercise or pharmacologic stress) within 21 days of enrollment, using 99mTc-labeled tracer...
BMS747158 is an investigational small molecule being studied for use in cardiovascular imaging, specifically for cardiac PET perfusion imaging to assess conditions like ischemia and coronary artery disease. It has been evaluated in clinical trials involving healthy volunteers and patients with these cardiac conditions.
BMS747158 is a small molecule developed for cardiac PET perfusion imaging. It is designed to assess myocardial blood flow and detect areas of ischemia or coronary artery disease. The specific molecular target has not been disclosed in the available clinical trial information.
BMS747158 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. The company has conducted clinical trials to evaluate the safety and imaging capabilities of this investigational agent.
BMS747158 is in clinical development, with trials ranging from Phase 1 to Phase 2. The most advanced completed trial was a Phase 2 study evaluating a rest/stress cardiac PET perfusion imaging protocol. It is not approved by the FDA and remains an investigational agent.
BMS747158 has been studied in several completed clinical trials, including NCT00707499 and NCT00707538, which were Phase 1 safety studies in healthy volunteers. NCT00849108 was a Phase 2 trial in patients with ischemia, and NCT00930631 was a Phase 1 study in healthy male subjects with coronary artery disease.
BMS747158 is also known as flurpiridaz F 18, a radioactive tracer used for cardiac PET imaging. It is being developed by Lantheus Holdings, Inc. for the detection of coronary artery disease and myocardial ischemia.